OnabotulinumtoxinA Alters Pro- and Anti-Inflammatory Dural Macrophage Response to CSD in Female Mice - Aaron J. Schain; Diego Delgado Fajardo; Andrew M. Strassman; Subhash Kulkarni; Ron S. Broide; Amy D. Brideau-Andersen; Aubrey Manack Adams; Mitchell F. Brin; Rami Burstein (Toxicon, 2026)

OnabotulinumtoxinA Inhibits Dysregulation of Descending Pain Modulation Following Mild Traumatic Brain Injury in Mice - Robson C. Lillo Vizin; Caroline M. Kopruszinski; Janice N. Oyarzo; David W. Dodick; Ron S. Broide; Amy D. Brideau-Andersen; Mitchell F. Brin; Trent Anderson; Edita Navratilova; Frank Porreca (Toxicon, 2026)

Rat Grip Strength Is a Sensitive and Reproducible Measure of OnabotulinumtoxinA-Induced Muscular Weakness - Deirdre J. La Placa; Shalu Sharma Kharkwal; Nicola J. Broadbent; Amy D. Brideau-Andersen; Ron S. Broide (Toxicon, 2026)

Pharmacological Differences Between Botulinum Toxin Type A 900 kDa Complex and 150 kDa Neurotoxin Protein - Ron S. Broide; Greg Nicholson; Michelle Cano; Dave Canty; Terry Boodhoo; Amy D. Brideau-Andersen; Mitchell F. Brin (Toxicon, 2026)

Botulinum Neurotoxin Type A Signaling in Pain Modulation Within Human Sensory Neurons - Paulino Barragan-Iglesias; Katherin A. Gabriel; Kali Hankerd; Amy D. Brideau-Andersen; Lance E. Steward; Steve McGaraughty; Edwin Vazquez-Cintron; Theodore J. Price (Toxicon, 2026)